Eli Lilly Stock Before Q4 Earnings: To Buy or Not to Buy?
Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.72 billion and $5.15 per share, respectively. Earnings estimates for 2025 have declined from $24.05 to $23.57 per share over the past 30 days.
Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...
Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...
Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...
Eli Lilly and Company (NYSE:LLY – Get Free Report) traded up 0.1% during mid-day trading on Monday after Truist Financial raised their price target on the stock from $1,029.00 to $1,038.00. Truist ...
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...
Eli Lilly is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid ...
Erste Group analysts upgraded Eli Lilly stock from Hold to Buy, citing a robust product demand and a promising pipeline of potential successes. The analysts highlighted the pharmaceutical company's ...
Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback